Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy Journal Article

  

Authors:	Zivanovic, O.; Leitao, M. M. Jr; Park, K. J.; Zhao, H.; Diaz, J. P.; Konner, J.; Alektiar, K.; Chi, D. S.; Abu-Rustum, N. R.; Aghajanian, C.
Article Title:	Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy
Abstract:	Objectives: To analyze progression-free (PFS) and overall survival (OS) in patients with small cell neuroendocrine carcinoma of the cervix (SCNEC), and to determine whether platinum-based combination chemotherapy is beneficial for this population. Methods: We performed a retrospective analysis of all patients with SCNEC who were treated at our institution between 1/1990 and 2/2007. Patients were excluded if pathologic diagnosis was not confirmed at our institution. Standard statistical methods were utilized. Results: Seventeen patients met inclusion criteria. The estimated 3-year PFS and OS rates for the entire group were 22% and 30%, respectively. Median time to progression was 9.1 months. Extent of disease was the only significant prognostic factor. Median OS for patients with early stage disease (IA1-IB2) was 31.2 months and 6.4 months for patients with advanced stage disease (IIB-IV, P = 0.034). In the early-stage disease group, the 3-year distant recurrence-free survival rate was 83% for patients who received chemotherapy and 0% for patients who did not receive chemotherapy as part of their initial treatment (P = 0.025). The estimated 3-year OS rate was 83% for patients who received and 20% for patients who did not receive chemotherapy as part of their initial treatment (P = 0.36). Conclusion: Given the rarity of SCNEC this retrospective analysis is limited by a small number of patients. However, the natural history of this rare disease is akin to small cell lung cancer and the prognosis is poor due to the tumor's propensity for distant spread. The treatment should conform to the treatment of small cell lung cancer. © 2008 Elsevier Inc. All rights reserved.
Keywords:	adult; cancer survival; clinical article; treatment outcome; middle aged; retrospective studies; overall survival; cancer recurrence; cisplatin; advanced cancer; cancer combination chemotherapy; cancer growth; neoplasm staging; carboplatin; progression free survival; multiple cycle treatment; neoplasm recurrence, local; etoposide; antineoplastic combined chemotherapy protocols; retrospective study; neuroendocrine tumor; early cancer; platinum derivative; uterine cervical neoplasms; cervix; uterine cervix carcinoma; small cell carcinoma; carcinoma, neuroendocrine; carcinoma, small cell; platinum-based chemotherapy; small cell neuroendocrine carcinoma
Journal Title:	Gynecologic Oncology
Volume:	112
Issue:	3
ISSN:	0090-8258
Publisher:	Elsevier Inc.
Date Published:	2009-03-01
Start Page:	590
End Page:	593
Language:	English
DOI:	10.1016/j.ygyno.2008.11.010
PUBMED:	19110302
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-60449109704&partnerID=40&md5=96808ab33f10768778f0dbd33466ad61
Notes:	--- - "Cited By (since 1996): 2" - "Export Date: 30 November 2010" - "CODEN: GYNOA" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/1788